[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-sclerosis-secondary-progressive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-sclerosis-secondary-progressive":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,76,106,134,156,177,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100537346","intermittent-hypoxia-in-persons-with-multiple-sclerosis-100537346",false,"NCT06276634","Intermittent Hypoxia in Persons With Multiple Sclerosis","Intermittent Hypoxia Initiated Motor Plasticity in Individuals With Multiple Sclerosis","Inclusion Criteria:\n\n* Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)\n* Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5\n* Motor Functional System Scale (FSS) between 2-4\n* Relapse free for at least 1 year\n* Age ≥ 18 years and ≤ 75 years\n* Safe to be scanned based on MRI questionnaire\n* Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening\n\nExclusion Criteria:\n\n* Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan\n* Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)\n* History of epilepsy\n* Chronic obstructive pulmonary disease\n* Uncontrolled Sleep apnea\n* Pregnancy","ALL","18 Years","75 Years",{"count":20,"type":21},21,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.",[27,28,29],"Multiple Sclerosis","Multiple Sclerosis-Relapsing-Remitting","Multiple Sclerosis, Secondary Progressive",[31,32,33],"multiple sclerosis","AIH","Hypoxia","RECRUITING","2026-03-18",{"date":37,"type":38},"2026-03-20","ACTUAL",{"date":40,"type":38},"2024-04-30",{"date":42,"type":21},"2027-01",{"name":44,"class":45},"Shirley Ryan AbilityLab","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100526698","phase-1-a-study-of-anti-cd19-chimeric-antigen-receptor-t-cell--car-t-therapy-in-subjects-with-non-relapsing-and-progressive-forms-of-multiple-sclerosis-100526698","NCT06138132","A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis","A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis","Inclusion Criteria:\n\n1. Patient is ≥ 18 years old, and ≤65 years of age, at time of screening visit.\n2. Diagnosis of MS according to the 2017 McDonald Criteria.\n3. Progressive MS by 2014 Lublin MS phenotypic criteria.\n4. Presence of varicella-zoster virus (VZV) antibodies, or completion of at least one dose of the varicella zoster glycoprotein E (gE) Shingrix vaccine at least four weeks prior to treatment.\n5. Presence of anti EBV antibodies.\n6. Organ and Marrow Function\n\n   * Absolute neutrophil count (ANC) ≥ 2000\u002FuL.\n   * Platelet count ≥ 150,000\u002FuL.\n   * Absolute lymphocyte count ≥ 1000\u002FuL.\n   * Serum immunoglobulin G (IgG) ≥ 500mg\u002FdL.\n   * Hemoglobin ≥ 9 g\u002FdL.\n   * Adequate renal, hepatic, pulmonary and cardiac function defined as:\n\n     * Creatinine ≤ 2mg\u002FdL or creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL\u002Fmin.\n     * Serum alanine transaminase (ALT)\u002Faspartate aminotransferase (AST) ≤ 3 upper limit of normal (ULN).\n     * Total bilirubin ≤ 1.5 mg\u002Fdl, except in subjects with Gilbert's syndrome\n     * Cardiac ejection fraction ≥ 40%, no evidence of physiologically significant pericardial effusion as determined by an ECHO, and no clinically significant ECG findings.\n     * Baseline oxygen saturation \\> 94% on room air.\n7. Testing for\n\n   * Hepatitis B core antibody (HBc Ab)\n   * Hepatitis C antibody (HCV Ab)\n   * Hepatitis B surface antigen (Hep B surf. AG)\n   * HIV 1\\&2 Ab\n   * Syphilis Screen\n   * Human T-cell lymphotropic virus (HTLV) Ab I \\& II\n   * Nucleic acid test multiplex (NAT MPX) for HIV, HCV, HBV\n   * Herpes Simplex Virus 1 \\& 2 IgG panel\n   * Varicella-Zoster (VZ) IgG\n   * Cytomegalovirus (CMV) Total Ab\n\n   Must be seronegative for HIV-1 RNA polymerase chain reaction (PCR); HIV 1 and HIV 2 Ab (antibody); HTLV-1 and HTLV-2 Ab; PCR+ or negative surface antigen for hepatitis B; negative for the Treponema pallidum antibody Syphilis screen; and negative for HIV-1 and hepatitis C by nucleic acid testing (NAT) within 40 days of apheresis procedures.\n8. Females of childbearing potential have a negative serum or urine pregnancy test because of the potentially dangerous\u002Funknown effects on the fetus. Females who have undergone hysterectomy or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential.\n9. Contraception: Subjects of child-bearing or child-fathering potential must be willing to practice highly effective birth control from the time of enrollment on this study and for the entire study period which is 12 months after receiving the CAR T cell infusion.\n10. Ability to understand and the willingness to sign a written informed consent document. Patients must have signed informed consent to participate in the trial.\n11. Adequate vital sign criterion with acceptable numerical ranges of:\n\n    * Systolic Blood Pressure (mmHg) ≥ 100 and ≤ 150\n    * Diastolic Blood pressure (mmHg) ≥ 60 and ≤ 90\n    * To ensure subject safety and stability, any subject who is noted to have a BP \\> 150\u002F90 mm Hg should be stable on anti-hypertensive medications with repeated BP ≤150\u002F90 for at least one month prior to enrollment in the study\n    * Heart Rate ≥ 60 and ≤ 100 bpm\n    * Oral Temperature ≤ 37.7 C\u002Fafebrile\n    * Respiratory rate ≥ 12 and ≤ 20bpm\n\nExclusion Criteria:\n\n1. History of neuromyelitis optica spectrum disorder (NMOSD) or MOG antibody associated disease (MOGAD).\n2. Prior treatment with any investigational agent within 3 months, or 5 half-lives, whichever is longer. Agents authorized by the FDA for prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not considered investigational.\n3. Initiation of any DMT between the completion of apheresis and start of lymphodepletion (LD) chemotherapy. The use of methylprednisolone for bridging therapy between apheresis and start of LD chemotherapy will be allowed.\n4. History of CNS or spinal cord tumor, metabolic or infectious cause of myelopathy, genetically inherited progressive CNS disorder, sarcoidosis or non-MS progressive neurologic condition affecting ability to perform study assessments.\n5. History of cytopenia consistent with the diagnosis of myelodysplastic syndrome (MDS).\n6. History of sickle cell anemia or other hemoglobinopathy.\n7. Coagulation abnormalities defined by: international normalized ratio (INR) \\> 1.5, prothrombin time (PT) \\> 14 seconds, partial thromboplastin time (PTT) \\> 45 seconds to the exclusion criteria. Patients with positive antiphospholipid antibodies, including anti-cardiolipin, or lupus anticoagulant.\n8. Presence of fungal, bacterial, viral, or other infection that is not controlled and\u002F or requiring hospitalization or treatment with IV antimicrobials within 4 weeks of screening. Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.\n9. Psychiatric disorder(s) or psychosocial circumstance(s) which in the opinion of the Stanford Transplant team caring for this potential patient would place the patient at an unacceptable risk.\n10. Presence or history of liver cirrhosis.\n11. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years\n12. Active infection with HIV, hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive) as the immunosuppression contained in this study may pose unacceptable risk. A prior history of hepatitis B or hepatitis C is permitted providing the viral load is undetectable per quantitative PCR and\u002For nucleic acid testing. Hepatitis B surface antibody following hepatitis B immunization is not considered to be evidence of past infection.\n13. Central nervous system (CNS) disorder such as cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease unrelated to MS that in the judgment of the investigator may impair the ability to evaluate neurotoxicity.\n14. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease (uncontrolled congestive heart failure) within 4 months of enrollment. Subjects with stable cardiac disease fulfilling inclusion criteria are allowed.\n15. Subjects receiving anticoagulation therapy or subjects with concomitant use of antiplatelet agents.\n16. History of Crohn's, rheumatoid arthritis, systemic lupus that required continued systemic immunosuppression\u002Fsystemic disease modifying agents within the 2 years prior to trial enrollment.\n17. A primary immune deficiency disease\n18. In the investigator's judgment, the subject is unlikely to complete protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.\n19. History of severe immediate hypersensitivity reaction to any of the agents used in this study. This includes contraindications or life-threatening allergies, hypersensitivity, or intolerance to KYV-101 or its excipients, including dimethyl sulfoxide; Bendamustine; or tocilizumab.\n20. Any medical condition that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of study treatment.\n21. Prior treatment with total lymphoid irradiation or mitoxantrone exceeding 36 mg\u002Fm2 cumulative dose\n22. Prior treatment with autologous hematopoietic stem cell transplantation, or prior history of cellular immunotherapy (eg. CAR T) or gene therapy directed at any target.\n23. Prior treatment with anti-CD20+ monoclonal antibody therapy within 9 months of trial initiation. A 30-day washout will be required for prior treatment with glatiramer acetate, interferon-beta, and fumarates. A 60-day washout will be required for sphingosine-i-phosphate modulators and natalizumab. Excluded will be patients who received prior treatment with mitoxantrone regardless of prior cumulative dose.\n24. Prior history of solid organ transplantation\n25. Impaired cardiac function or clinically significant cardiac disease including:\n\n    * a. Unstable angina or myocardial infarction or coronary artery bypass graft (CABG) within 6 months prior to apheresis.\n    * b. New York Heart Association (NYHA) stage III or IV congestive heart failure.\n    * c. History of clinically significant cardiac arrhythmia (eg, ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular (AV) block.\n    * d. History of severe nonischemic cardiomyopathy.\n    * e. Left ventricular ejection fraction (LVEF) \\\u003C45% as assessed by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan (performed ≤8 weeks of apheresis).\n    * f. Active, current cardiac manifestations of systemic lupus erythematosus (SLE) including pericarditis, pericardial effusion, and myocarditis.\n26. Prior history of splenectomy\n27. History of moderate or worse than moderate asthma or chronic obstructive pulmonary disease (COPD)\n28. Corrected QT interval (QTc) \\>450msec in males or \\>470msecs in females\n29. Subjects with valvular heart disease (regurgitation, stenosis or atresia\n30. Moderate or worse renal impairment using criteria\n\n    * Stage 1: Kidney damage with normal or increased GFR (\\>90 mL\u002Fmin\u002F1.73 m\\^2).\n    * Stage 2: Mild reduction in GFR (60-89 mL\u002Fmin\u002F1.73 m\\^2).\n    * Stage 3a: Moderate reduction in GFR (45-59 mL\u002Fmin\u002F1.73 m\\^2).\n    * Stage 3b: Moderate reduction in GFR (30-44 mL\u002Fmin\u002F1.73 m\\^2).\n    * Stage 4: Severe reduction in GFR (15-29 mL\u002Fmin\u002F1.73 m\\^2).\n    * Stage 5: Kidney failure (GFR \\\u003C 15 mL\u002Fmin\u002F1.73 m\\^2 or dialysis)\n31. Previously received Mavenclad, yet drug washout is ≤9 months.\n32. History of a seizure disorder even if the seizure disorder is well controlled with anti-epileptics\n33. Prior history of treatment with cellular immunotherapy (e.g. CAR T) gene therapy product directed as any target.","65 Years",{"count":56,"type":21},12,[58],"PHASE1","A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis",[27,61,29],"Multiple Sclerosis, Primary Progressive",[63,64,65,66],"KYV-101","autoimmune disease","anti-CD19 CAR-T therapy","cellular therapy","2026-02-24",{"date":69,"type":38},"2026-02-27",{"date":71,"type":38},"2024-04-10",{"date":73,"type":21},"2027-06",{"name":75,"class":45},"Stanford University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100546130","effects-of-acute-intermittent-hypoxia-on-neuroplasticity-in-ms-100546130","NCT06390930","Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS","Investigating the Effects of Acute Intermittent Hypoxia on Neuroplasticity in Persons With Multiple Sclerosis","Inclusion Criteria:\n\n* Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago\n* Relapse free for at least 6 months\n* Expanded Disability Status Scale (EDSS) ≤7\n* Index finger abduction strength \\\u003C5 according to Medical Research Council Scale, or 9-Hole Peg Test score \\>20 seconds in at least one hand\n* Stable disease modifying therapies for at least 6 months\n* Individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening\n\nExclusion Criteria:\n\n* Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function\n* Mini-Mental State Examination (MMSE) score \\\u003C24\n* Modified Ashworth Scale score \\>3 on elbow joint\n* Uncontrolled hypertension or hypotension (outside 140\u002F90 and 85\u002F55 mmHg)\n* History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea\n* Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain\n* Pregnancy as confirmed by urine test",{"count":84,"type":21},22,[24],"This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.",[27,88,29],"Multiple Sclerosis, Relapsing-Remitting",[31,90,91,92,93,94,95,96,97],"plasticity","neuroplasticity","motoneuron","aih","hypoxia","Acute Intermittent Hypoxia","arm","upper extremity","2026-02-19",{"date":100,"type":38},"2026-02-23",{"date":102,"type":38},"2025-02-01",{"date":104,"type":21},"2027-07",{"name":44,"class":45},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":46},"100556535","clinnova-ms-a-prospective-cohort-study-of-patients-with-multiple-sclerosis-switzerland-100556535","NCT06526364","Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)","Clinnova-MS: a Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care (Switzerland)","Inclusion Criteria:\n\n* Age ≥18\n* Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations.\n* Signed informed consent form\n* In possession of a Healios+Me app compatible smartphone (iOS\u002FAndroid)\n* Corrected close visual acuity of ≥0.5\n* Hand motor skills sufficient for using a smartphone\n* Ability to follow the study procedures\n* Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (clinically isolated syndrome, RRMS, SPMS, PPMS) AND early disease stages (\\\u003C 3 years) OR transitioning phase to progressive disease as evaluated based on Expanded Disability Status Scale (EDSS).\n* Enrolled in the SMSC at University Hospital Basel\n\nThere are no specific exclusion criteria.",{"count":114,"type":21},100,"OBSERVATIONAL","This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.",[27,88,61,29],[119,120,121,122,123,124],"Immune-meditated Diseases","Artificial Intelligence","Personalized medicine","Treatment change","Phenotyping","Clinnova","2025-12-18",{"date":127,"type":38},"2025-12-26",{"date":129,"type":38},"2024-12-10",{"date":131,"type":21},"2029-06",{"name":133,"class":45},"University Hospital, Basel, Switzerland",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100585271","phase-1-a-study-of-allogeneic-hematopoietic-cell-transplantation-for-primary-progressive-multiple-sclerosis-100585271","NCT06900192","A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis","A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Using Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood","Inclusion Criteria (Recipient):\n\n1. Participants aged ≥18 and ≤65 years with primary progressive multiple sclerosis\n2. A diagnosis of PPMS by 2017 McDonald criteria and 2013 clinical course revision102\n3. CSF with elevated IgG index or 2 or more oligoclonal bands\n4. EDSS (see Appendix 9) between 2.0 and 5.5 inclusive\n5. Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less).\n6. Eligibility criteria confirmed by the Eligibility Review Group (Appendix 10)\n7. Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as described in Appendix 14 prior to their planned day 0.\n8. Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT.\n9. Ability to undergo MRI without general anesthesia\n10. Ability to undergo all tests and procedures in the study\n11. Patients who are not vaccinated for COVID-19 must have no symptoms of COVID-19 and have negative testing for COVID-19. For other vaccine-preventable illnesses, it is recommended that patients are current on their vaccination schedule.\n\nExclusion Criteria:\n\n1. History of Progressive Multifocal Leukoencephalopathy\n2. Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:\n\n   1. Renal insufficiency as defined by an estimated GFR \\\u003C60 mL\u002Fminute\n   2. Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or left ventricular ejection fraction \\\u003C50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)\n   3. Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a FEV1 \\\u003C70% expected and\u002For a DLCOadj \\\u003C70% expected.\n   4. Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension\n   5. Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an absolute neutrophil count (\\\u003C1000\u002Fmm3) below the lower limit of normal, or a platelet count below 50,000\u002Fmm3.\n   6. Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy.\n   7. Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy.\n   8. Extreme protein-calorie malnutrition defined by Body Mass Index \\\u003C18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)\n3. History of smoking either tobacco or other herbal products in the last 3 months.\n4. Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), eg, cladribine, or peritransplant antithymocyte globulin (ATG). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of infusion Orca-Q Prime). The washout period for alemtuzumab is listed in Appendix 14.\n5. HIV seropositive.\n6. HBV serology results indicating chronic HBV infection per https:\u002F\u002Fwww.cdc.gov\u002Fhepatitis\u002Fhbv\u002FinterpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant.\n7. HCV seropositive, unless PCR negative and having undergone 'curative' antiviral therapy.\n8. Participant has active uncontrolled infection\n9. Participant has demonstrated lack of compliance with prior medical care\n10. Participants with known active malignancy. It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN \\[The National Comprehensive Cancer Network®\\] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.\n11. Participants whose life expectancy is severely limited by illness other than multiple sclerosis\n12. Females who are pregnant or breast feeding.\n13. Medical or psychiatric conditions that compromise ability to give informed consent or to comply with treatment protocol\n14. Inability to undergo an MRI scan\n15. Currently receiving treatment with investigational agents\n16. Positive for JC virus DNA in the CSF or blood during screening.",{"count":142,"type":21},10,[58],"A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).",[146,27,61,29],"Primary Progressive Multiple Sclerosis","NOT_YET_RECRUITING","2025-03-26",{"date":150,"type":38},"2025-03-28",{"date":152,"type":21},"2025-03",{"date":154,"type":21},"2029-08",{"name":75,"class":45},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":164,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":46},"100555774","development-of-camera-based-gait-quality-measure-for-persons-with-multiple-sclerosis-100555774","NCT06516458","Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis","Development of Camera Based Gait Deviation Index for Persons With Multiple Sclerosis","MS-GDI","Inclusion criteria:\n\n* Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS)\n* Able to ambulate overground\n* Relapse free for at least 1 month\n* Age ≥18 and ≤ 75 years\n* Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening\n\nExclusion criteria:\n\n\\- Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing",{"count":165,"type":21},40,"The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).",[27,29,168,88],"Multiple Sclerosis Relapse","2024-07-18",{"date":171,"type":38},"2024-07-24",{"date":173,"type":21},"2024-07",{"date":175,"type":21},"2026-07",{"name":44,"class":45},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":185,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":188,"conditions":189,"keywords":197,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":46},"100454970","ms-researchbiomarkers-100454970","NCT05204459","MS-ResearchBiomarkerS","Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders","MS-ReBS","Inclusion Criteria:\n\n* Subjects who meet any one of the following diagnostic criteria:\n\n  * Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria.\n  * Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria.\n  * Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease.\n  * Diagnosis of neurological disorders other than MSRD.\n  * Healthy volunteer.\n* Age ≥18.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves).\n* Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study.\n* Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT\u002FOCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).",true,{"count":187,"type":21},1000,"This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and\u002For spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.",[27,88,61,29,190,191,192,193,194,195,196],"Clinically Isolated Syndrome","Radiologically Isolated Syndrome","Neuromyelitis Optica Spectrum Disorders","Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","Neurologic Autoimmune Disease","Neurologic Disorder","Healthy Aging",[27,88,61,29,190,191,192,198,194,195,196],"Myelin oligodendrocyte glycoprotein antibody-associated disease","2024-02-05",{"date":201,"type":38},"2024-02-06",{"date":203,"type":38},"2021-11-11",{"date":205,"type":21},"2041-11-11",{"name":207,"class":45},"Cedars-Sinai Medical Center",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":54,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":46},"100513144","phase-2-cladribine-vs-placebo-for-non-active-progressive-multiple-sclerosis-clasp-ms-100513144","NCT05961644","Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).","Safety and Efficacy of Subcutaneous Cladribine for Nonrelapsing, Secondary Progressive Multiple Sclerosis (CLASP-MS): a Randomized, Placebo-controlled, Double-blind, Phase 2 Study.","CLASP-MS","Inclusion Criteria:\n\n* Written informed consent\n* Diagnosis of relapse-onset, secondary progressive multiple sclerosis based on the 2017 McDonald criteria\n* Progression of disability over 24 months defined as an increase in the EDSS score of 1 or more for patients with EDSS ≤ 5.5 or of 0.5 or more for patients with EDSS \\> 5.5\n* Lack of relapses over last 12 months\n* EDSS of 3.5 - 7.5 inclusive\n* Age of 30 - 65 years inclusive\n* Duration of MS of 10 years or longer\n* Pre-menopausal women must refrain from heterosexual intercourse or use a contraception method with a failure rate of \\\u003C 1% from enrolment up to 6 months after the last dose of the investigational medicinal product\n* Men must refrain from heterosexual intercourse from enrolment up to 6 months after the last dose of the investigational medicinal product or use a barrier method of contraception, with their female partners using a contraception method with a failure rate of \\\u003C1%\n* Able to fulfill all protocol requirements as judged by the investigator\n\nExclusion Criteria:\n\n* Lack of written informed consent\n* Previous cladribine treatment\n* Hypersensitivity to the investigational medicinal product\n* Eligible and willing to use interferon beta, siponimod, or mitoxantrone\n* Unable to undergo magnetic resonance imaging\n* Pregnancy or breastfeeding\n* Does not agree to use contraception methods defined above\n* Diseases of the nervous system, such as tumors, stroke, traumatic injury, encephalomyelitis, B12 deficiency, or demyelinating diseases other than multiple sclerosis\n* Major comorbidities, such as cancer, liver failure, kidney failure, heart failure (NYHA II-III), or any other disease that may jeopardize patient safety or make it impossible for the patient to fulfill protocol requirements\n* Relapse within last 12 months\n* Chronic treatment with corticosteroids or immunosuppressants (eg, azathioprine, methotrexate, cyclosporine) within last 6 months\n* Disease-modifying treatments for multiple sclerosis (no washout is required for interferons beta, glatiramer acetate, and dimethyl fumarate; washout of \\> 6 months for teriflunomide, fingolimod, and natalizumab \\[an accelerate elimination procedure may be used for teriflunomide instead\\]; washout of \\> 12 months for ocrelizumab, mitoxantrone, and alemtuzumab)\n* Relapsing-remitting multiple sclerosis\n* Primary progressive multiple sclerosis\n* Hepatitis B or hepatitis C, including detectable HbsA, anti-HBc, or anti-HCV antibodies in serum\n* HIV infection, including a positive screening test (anti-HIV 1\u002F2, protein 24)\n* Active or latent tuberculosis, including a positive result of the QuantiFERON TB Gold test during screening or within 3 months (an inconclusive test must be repeated; two inconclusive tests are taken as a positive result)\n* Other infection that may be worsened by treatment with cladribine\n* Lymphopenia (\\\u003C 1000\u002Fμl), neutrocytopenia (\\\u003C 1500\u002Fμl), or thrombocytopenia\n* Alanine aminotransferase or aspartate aminotransferase \\> 2 x ULN (can be repeated when 1.5-3x ULN); Total bilirubin \\> 1.5 x ULN (can be repeated when 1.5-3 x ULN); Hemoglobin \\> 9.5 g\u002FdL (can be repeated when 9-9.4 g\u002FdL)\n* Lack of vaccination against COVID-19 - the time from the last dose of a full vaccination regimen is shorter than 6 weeks\n* Any vaccination within last 6 weeks\n* Lack of cancer screening or suspicion of cancer or necessity to carry out additional studies after the following examinations done at screening: chest X-ray in all participants; mammography or breast ultrasound in women; cervical smear in women; prostate-specific antigen in men\n* Patient does not have detectable antibodies against Varicella zoster virus in serum or a proof of two-dose vaccination against this virus (last dose at least 6 months before enrolment)\n* Use of oral or parenteral anticoagulants or antiplatelets other than acetylsalicylic acid","30 Years",{"count":218,"type":21},188,[220,221],"PHASE2","PHASE3","The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease progression of non-active secondary progressive multiple sclerosis.\n\nMultiple sclerosis is an inflammatory disease of the central nervous system. In most patients, it starts with a relapsing course (RMS) which is caused by acute inflammatory lesions in the brain and spinal cord. RMS transforms at later stages into progressive disease (secondary progressive MS). Currently approved disease-modifying treatments are effective in reducing clinical relapses and brain and spinal lesions visible in MR, but they perform poorly in preventing disease progression and overall disability accumulation. The growing evidence shows that disease progression partially depends on chronic inflammation present in the CNS. Drugs, which may cross the blood-brain barrier and reach inflammatory cells residing in the CNS might be effective in this stage of the disease. Cladribine is one of the DMT approved for RMS. It is a synthetic purine analog with selective lymphocyte toxicity, which enter the CNS and is found in cerebrospinal fluid. In patients treated with cladribine, the oligoclonal bands tend to disappear proving that neuroinflammation is diminished.\n\nThe participants of this clinical trial with the later non-active stage of MS are enrolled to be treated with cladribine subcutaneously or a non-active comparator (placebo) for 6 months and followed for the next 2 years, with an MRI scan and clinical evaluation every 6 months. The main questions it aims to answer are if in the non-active stage of MS cladribine is potent to lessen brain volume loss and if it is potent to attenuate inflammation in the CNS.",[29,27],[225,226,227,228,229,230],"Cladribine","Multiple Sclerosis Secondary Progressive","Brain Volume","Quantitative Susceptibility Mapping","Magnetic Resonance Imaging","Cognitive assessment","2023-07-26",{"date":233,"type":38},"2023-07-28",{"date":235,"type":38},"2022-10-03",{"date":237,"type":21},"2027-10-30",{"name":239,"class":45},"Institute of Psychiatry and Neurology, Warsaw"]